LI Hao
Department: School of Medicine
Research area:Pharmacology
(1)Fang-Hong Shi(#),Hao Li (#),Long Shen(#),Zhen Zhang,Yi-Hong Jiang,Yao-Min Hu,Xiaoyan Liu,Zhichun Gu(*),Jing Ma(*),Houwen Lin(*). Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Frontiers in Pharmacology, 2019, 10, 1066 (SCI,2018IF:3.845)
(2)Hao Li,Shi-Ying Huang,Fang-Hong Shi(*),Shun-Guo Zhang,Zhi-Chun Gu,Ji-Fu Wei(*),α4β7 Integrin Inhibitors: A Patent Review,Expert Opinion On Therapeutic Patents,2018,28(12):903-917(PMID: 30444683)(SCI,2018IF:3.699)
(3)Hao Li,Fang-Hong Shi(*),Shi-Ying Huang,Shun-Guo Zhang(*),Min-Ling Chen,A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-alpha4 Integrin Monoclonal Antibody,Current Drug Metabolism,2018,19(14):1202-1212 (PMID:29708072)(SCI,2018IF:2.277)
(4)Hao Li(#), Shi-Ying Huang(#), Shun-Guo Zhang(#), Min-Ling Chen, Zhi-Chun Gu(*),Fang-Hong Shi(*), Protocol for a Systematic Evaluation of Pediatric Pharmacy Development and Pediatric Pharmacy Experts Research Area in China,Medicine,2018,97(50):e13597(SCI,2018IF:1.870)
(5)Hao Li(#),Fang-Hong Shi(#),Shi-Ying Huang,Shun-Guo Zhang,Zhi-Chun Gu(*),Ji-Fu Wei(*),Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails,Medicine,2018,97(28):e11507(SCI,2018IF:1.870)

(6)Hao Li(#),Fang-Hong Shi(#),Shi-Ying Huang(#),Shun-Guo Zhang(*),Zhi-Chun Gu(*),Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis,Medicine,2018,97(32):e11853(SCI,2018IF:1.870)

(7)Fang-Hong Shi(#),Hao Li(#),Min Cui,Zai-Li Zhang, Zhi-Chun Gu(*),Xiao-Yan Liu(*),Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,Frontiers in Pharmacology,2018,9:576 (SCI,2018IF:3.845)

(8)Fang-Hong Shi(#),Hao Li(#),Min Cui,Zai-Li Zhang,Zhi-Chun Gu(*),Xiao-Yan Liu(*),Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis,Medicine,2018,97(16):e0420(SCI,2018IF:1.870)
(9)Hao Li,Ling Meng,Fei Liu,Wei Ji-Fu(*),Yong-Qing Wang(*),H+/K+-ATPase inhibitors: a patent review,Expert Opinion On Therapeutic Patents,2013,23(1):99 ~ 111(SCI,2018IF:3.699)
(10)Hao Li,Kun Xu,Yongqing Wang(*),Hongwen Zhang,Tianping Li,Ling Meng,Xiaojian Gong(*),Haibo Zhang,Ning Ou,Jinman Ruan,Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions,Drugs in R&D,2012,12(2):65 ~ 70(SCI,2012IF:1.707)

Xinjian Building,Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai, China